Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086500 | 0.89 | KMT2A (0.44) | KMT2AL3MBTL1OPRK1ESR2 | |
| SCHEMBL8914329 | 0.77 | ALDH1A1 (0.47) | KMT2AL3MBTL1OPRK1USP2 | |
| SCHEMBL5690573 | 0.75 | L3MBTL1 (0.50) | KMT2AL3MBTL1BCHEMAPTESR2 | |
| SCHEMBL30686540 | 0.74 | HTR2C (0.51) | ESR2 | |
| SCHEMBL16237671 | 0.74 | SIGMAR1 (0.44) | KMT2AL3MBTL1OPRK1USP2 | |
| SCHEMBL14127784 | 0.73 | ESR2 (0.46) | KMT2AL3MBTL1BCHEMAPTESR2 | |
| SCHEMBL4579407 | 0.73 | KMT2A (0.56) | KMT2AMAPTESR2 | |
| SCHEMBL15421246 | 0.72 | CHRM2 (0.49) | KMT2AL3MBTL1USP2 | |
| SCHEMBL853058 | 0.72 | CHRM2 (0.49) | KMT2AL3MBTL1USP2 | |
| SCHEMBL10106310 | 0.72 | CHRM2 (0.49) | KMT2AL3MBTL1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328880-B1 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| EP-2328880-A2 | 6-SUBSTITUTED BENZOXAZINES AS 5-HT-5A RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010026110-A2 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | WO | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | KMT2A 1797/4885L3MBTL1 3586/4885BCHE 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.